Dr Stephan Kutzer, COO, Custom Manufacturing, Lonza.
- Contract covers the clinical phase 2 production of Bertilimumab (iCo-008), a human immunoglobulin monoclonal antibody under investigation for the treatment of several inflammatory disorders.
- Lonza will manufacture Bertilimumab at its mammalian development facility.
BASEL, SWITZERLAND: Lonza announced an exclusive contract for the production of Immune Pharmaceutical’s human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. As per the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.
“We are excited about this opportunity to support Immune Pharmaceutical’s growing pipeline, This partnership is a direct reflection of our commitment to emerging pharmaceutical companies as they advance through clinical phase milestones,”
said Dr Stephan Kutzer, COO, Custom Manufacturing, Lonza.
“Lonza understands the needs of emerging companies, providing assistance and flexibility, while maintaining the highest standards essential for regulatory compliance and successful partnering,” said Dr Daniel Teper, CEO, Immune.
Additionally, Immune strengthened its internal bio-manufacturing expertise by appointing to its Board of Directors, Dr David Naveh, formerly the Chief Technical Officer of Bayer Biologics Worldwide.
© WOC News